Abstract
Background: We estimated real-world vaccine effectiveness (VE) against COVID-19 infection, hospitalization, ICU admission, and death up to 13 months after vaccination. VE before and after the emergence of Omicron was investigated. Methods: We used registered data from the entire Swedish population above age 12 (n = 9,153,456). Cox regression with time-varying exposure was used to estimate weekly/monthly VE against COVID-19 outcomes from 27 December 2020 to 31 January 2022. The analyses were stratified by age, sex, and vaccine type (BNT162b2, mRNA-1273, and AZD1222). Results: Two vaccine doses offered good long-lasting protection against infection before Omicron (VE were above 85% for all time intervals) but limited protection against Omicron infection (dropped to 43% by week four and no protection by week 14). For severe COVID-19 outcomes, higher VE was observed during the entire follow-up period. Among individuals above age 65, the mRNA vaccines showed better VE against infection than AZD1222 but similar high VE against hospitalization. Conclusions: Our findings provide strong evidence for long-term maintained protection against severe COVID-19 by the basic two-dose schedule, supporting more efforts to encourage unvaccinated persons to get the basic two doses, and encourage vaccinated persons to get a booster to ensure better population-level protection.
Funder
SciLifeLab National COVID-19 Research Program
Swedish Research Council
FORMAS
Swedish Research Council for Sustainable Development
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference31 articles.
1. SARS-CoV-2 vaccine candidates in rapid development;Li;Hum. Vaccines Immunother.,2021
2. Genetic diversity and evolution of SARS-CoV-2;Phan;Infect. Genet. Evol.,2020
3. Ssentongo, P., Ssentongo, A.E., Voleti, N., Groff, D., Sun, A., Ba, D.M., Nunez, J., Parent, L.J., Chinchilli, V.M., and Paules, C.I. (2022). SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: A systematic review and meta-analysis. BMC Infect. Dis., 22.
4. (2022, August 20). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available online: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
5. European Centre for Disease Prevention and Control (2022, August 20). Epidemiological Update: Omicron Variant of Concern (VOC)—Data as of 16 December 2021 (12:00). Available online: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron-data-16-december.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献